BioXcel Therapeutics Files 8-K with Corporate Updates

TL;DR

BioXcel Therapeutics filed an 8-K on Feb 6, 2025, for corporate updates and financial filings.

AI Summary

BioXcel Therapeutics, Inc. filed an 8-K on February 6, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements with exhibits. The company, incorporated in Delaware, is based in New Haven, CT, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates routine corporate actions and the submission of financial information, which is important for investors to stay updated on the company's administrative and financial status.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate administrative updates and financial exhibit submissions, not significant operational or financial events.

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• February 6, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• New Haven, CT (location) — Principal Executive Offices
• 001-38410 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.001 B — registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
• $0.001 — nding shares of common stock, par value $0.001 per share (the "Common Stock"). As pre

Filing Documents

• tm255604d1_8k.htm (8-K) — 37KB
• tm255604d1_ex3-1.htm (EX-3.1) — 10KB
• 0001104659-25-009906.txt ( ) — 223KB
• btai-20250206.xsd (EX-101.SCH) — 3KB
• btai-20250206_lab.xml (EX-101.LAB) — 33KB
• btai-20250206_pre.xml (EX-101.PRE) — 22KB
• tm255604d1_8k_htm.xml (XML) — 4KB

03. Amendments to Articles of Incorporation or Bylaws; Change

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 6, 2025, BioXcel Therapeutics, Inc. (the "Company") filed an amendment (the "Certificate of Amendment") to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"). As previously disclosed, at its special meeting of stockholders held on January 28, 2025 (the "Special Meeting"), and upon the recommendation of the Company's Board of Directors (the "Board"), the Company's stockholders approved a certificate of amendment to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-5 and 1-for-30, as determined by the Board in its discretion (the "Charter Amendment"). On January 29, 2025, the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-16. The Company has filed the Charter Amendment to effect a 1-for-16 reverse stock split of its shares of Common Stock, to be effective as of 5:00 p.m. Eastern Time on February 7, 2025(the "Reverse Stock Split"). As a result of the Reverse Stock Split, every 16 shares of the Company's Common Stock issued or outstanding will be automatically reclassified into one validly issued, fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportional adjustments will be made to the number of shares of Common Stock awarded and available for issuance under the Company's equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company's outstanding stock options and other equity securities under the Company's equity incentive plans. All outstanding warrants will also be adjusted in accordance with the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOXCEL THERAPEUTICS, INC. Date: February 6, 2025 By: /s/ Richard Steinhart Richard Steinhart Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR